HawkInsight

  • Contact Us
  • App
  • English

GH Research prices $150M stock offering

Clinical-stage biopharmaceutical company GH Research (NASDAQ:GHRS) priced of its previously announced underwritten public offering in the U.S. of 10M ordinary shares at a public offering price of $15.00 per share. Total gross proceeds of ~$150M. The offering is expected to close on February 6, 2025.Underwriters have a 30-day option to purchase up to an additional 1.5M ordinary shares at the public offering price, less underwriting discounts and commissions.

Disclaimer: The views in this article are from the original Creator and do not represent the views or position of Hawk Insight. The content of the article is for reference, communication and learning only, and does not constitute investment advice. If it involves copyright issues, please contact us for deletion.

NewFlashHawk Insight
More